Information från ABG Sundal Collier

Här finner du information kring börsens mindre och medelstora bolag. Avsändare är ABG Sundal Collier, innehållet är inte skapat av placera.nu:s redaktion.

« Tillbaka

Prevas - Feedback from ABGSC's Investor Days

25 maj 2026

<a id="bm-comp-18122a67-6fab-4747-acf2-a93f40ff5b0d" name="bm-comp-18122a67-6fab-4747-acf2-a93f40ff5b0d" class="BMCustomAnchor"></a><table><tr><td bm-component-id="18122a67-6fab-4747-acf2-a93f40ff5b0d" style="vertical-align: top; width:100.000000%;"><ul><li>Prioritising profitability, targeting 12% EBITA margin</li><li>Building on the 15+ years of defence expertise</li><li>Disciplined M&amp;A approach, waiting for the right fit</li></ul></td></tr></table><a id="bm-comp-9091a886-846a-4c2a-a61a-5943ce2a19a9" name="bm-comp-9091a886-846a-4c2a-a61a-5943ce2a19a9" class="BMCustomAnchor"></a><table><tr><td bm-component-id="9091a886-846a-4c2a-a61a-5943ce2a19a9" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">A Nordic technical consulting firm</h3><p>Last week, we hosted Prevas CEO Magnus Wel&#233;n at ABGSC's Investor Days. The company is a technical consultancy focused on product and production development, specialised in engineering, defence, life science and energy. Founded in 1985 and listed since 1998, Prevas operates across three main markets: Sweden (~81% of total sales, including Norway and other operations), Finland (~12%) and Denmark (~8%). Defence in particular is the fastest growing segment, up 22% in Q1'26 and now representing ~17% of total sales.</p><h3 class="bm-h3">Takeaways from the presentation</h3><p>We took away three key points from the presentation. 1) The current main priority is not rapid growth but rather restoring profitability towards the 12% EBITA margin target, with the adj. EBITA margin having improved for three consecutive quarters. To get there, the company is continuing to adjust the business towards the demand picture seen today, and more specifically, putting extra focus on higher-margin niches such as EAM. 2) Defence was highlighted as a structurally attractive area, where Prevas has built up security systems, processes and customer understanding over 15 years. We also asked about concentration risk, and management said they are comfortable with the current ~17% exposure of total sales, viewing defence as a structural growth area that is here to stay. 3) On M&amp;A, the tone was disciplined, with management noting that new technologies, customer value and cultural fit all need to be right, so we expect M&amp;A activity to remain limited near-term.</p><h3 class="bm-h3">Gradual margin recovery underway</h3><p>As is well known in the consultancy sector, margins have been weighed down by lower demand, leading to increased competition and pricing pressure. Over time, Prevas has undergone several organisational and structural changes to meet demand, as Mr. Wel&#233;n also discussed, reflected in the one-offs in Q1'26. The result has been improving margins in recent quarters, with management sounding incrementally more positive than two quarters ago. We agree, seeing a gradual margin recovery continuing in the coming quarters, and expect the company to return to positive organic growth in H2'26.</p></td></tr></table><a id="bm-comp-87c38cda-7820-405a-bdcd-b6a27b8e79c0" name="bm-comp-87c38cda-7820-405a-bdcd-b6a27b8e79c0" class="BMCustomAnchor"></a><table><tr><td bm-component-id="87c38cda-7820-405a-bdcd-b6a27b8e79c0" style="vertical-align: top; width:100.000000%;"><table id="bm-img-b176afa6-2f78-4d1c-8b33-f0c3baa94316" class="bm-img-table xslt-img-empty xslt-img-include"><tr><td class="xslt-img-caption">Demand outcome and expectations</td></tr><tr><td><img bm-img-encrypt="b176afa6-2f78-4d1c-8b33-f0c3baa94316" bm-img-original-height="377" bm-img-original-width="793" bm-img-svg="image:image_upload/96473_75ba8987-04cb-427c-9710-b2596d52e726.svg" bm-img-width-hint="100%" id="bm-id-b176afa6-2f78-4d1c-8b33-f0c3baa94316" src="https://abgsc.bluematrix.com/images/image_upload/96473_75ba8987-04cb-427c-9710-b2596d52e726_733.png" svg="/nas/web/clients/abgsc/images/image_upload/96473_75ba8987-04cb-427c-9710-b2596d52e726.svg" width="726" alt="" title="" /></td></tr><tr><td class="xslt-img-source">Source: National Institute of Economic Research (Swe: Konjunkturinstitutet).</td></tr></table><table id="bm-img-63c4632d-2ca8-46c5-96aa-a3ba778a78e4" class="bm-img-table xslt-img-empty xslt-img-include"><tr><td class="xslt-img-caption">Net sales and y-o-y growth</td></tr><tr><td><img bm-img-encrypt="63c4632d-2ca8-46c5-96aa-a3ba778a78e4" bm-img-original-height="377" bm-img-original-width="793" bm-img-svg="image:image_upload/96473_4fadd819-e063-49f5-a9b1-8f019220f6f8.svg" bm-img-width-hint="100%" id="bm-id-63c4632d-2ca8-46c5-96aa-a3ba778a78e4" src="https://abgsc.bluematrix.com/images/image_upload/96473_4fadd819-e063-49f5-a9b1-8f019220f6f8_733.png" svg="/nas/web/clients/abgsc/images/image_upload/96473_4fadd819-e063-49f5-a9b1-8f019220f6f8.svg" width="726" alt="" title="" /></td></tr><tr><td class="xslt-img-source">Source: ABG Sundal Collier, Company data</td></tr></table><table id="bm-img-f453c6ff-8e1e-407e-a36b-0550e1204507" class="bm-img-table xslt-img-empty xslt-img-include"><tr><td class="xslt-img-caption">adj. EBITA and margins</td></tr><tr><td><img bm-img-encrypt="f453c6ff-8e1e-407e-a36b-0550e1204507" bm-img-original-height="377" bm-img-original-width="793" bm-img-svg="image:image_upload/96473_60684518-a5a4-4122-8911-9562da9cc80e.svg" bm-img-width-hint="100%" id="bm-id-f453c6ff-8e1e-407e-a36b-0550e1204507" src="https://abgsc.bluematrix.com/images/image_upload/96473_60684518-a5a4-4122-8911-9562da9cc80e_733.png" svg="/nas/web/clients/abgsc/images/image_upload/96473_60684518-a5a4-4122-8911-9562da9cc80e.svg" width="726" alt="" title="" /></td></tr><tr><td class="xslt-img-source">Source: ABG Sundal Collier, Company data</td></tr></table></td></tr></table>

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-07-14 Nexam Chemical - Solid Q2, profitability within r... Nexam Chemical Analys
2026-07-14 Nexam Chemical - Record sales and first positive ... Nexam Chemical Analys
2026-07-14 Eastnine - Warsaw to become the largest market Eastnine Analys
2026-07-13 Ascelia Pharma - CRL update Ascelia Pharma Analys
2026-07-13 Medicover - Steady as she goes Medicover Analys
2026-07-13 Arctic Paper - Pulp beats paper Arctic Paper Analys
2026-07-13 Studsvik - Gearing up for the new-build era Studsvik Analys
2026-07-10 StrongPoint - The American dream StrongPoint Analys
2026-07-10 Careium - The pressure valve starting to open Careium Analys
2026-07-10 StrongPoint - Solid Q2 performance StrongPoint Analys
2026-07-10 Careium - Growth's comeback tour continues Careium Analys
2026-07-09 Infrea - Road tripping with Netel Infrea Analys
2026-07-08 Alligo - Softer growth, but margin recovery conti... Alligo Analys
2026-07-08 Qliro - Key earnings drivers intact Qliro Analys
2026-07-07 Nexam Chemical - We expect a firmer sequential qu... Nexam Chemical Analys
2026-07-07 Eastnine - Adding in Warsaw Eastnine Analys
2026-07-06 Ovzon - No Q2 fireworks, but plenty of fuel Ovzon Analys
2026-07-05 StrongPoint - Steady through the transition StrongPoint Analys
2026-07-03 Ascelia Pharma - Complete Response Letter for Orv... Ascelia Pharma Analys
2026-07-03 Fastpartner - Positive development on IFPM guidan... Fastpartner Analys